* IRadimed Corp IRMD.OQ IRMD.O is expected to show a rise in
quarterly revenue when it reports results on October 29.
* The Winter Springs, Florida-based company is expected to
report a 35.1% increase in revenue to $10.4 million from $7.7
million a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for IRadimed Corp is for
earnings of 17 cents per share. For the same quarter last year,
the company reported earnings of 11 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 2 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for IRadimed Corp
is $38, about 6.4% above its last closing price of $35.57.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Jun. 30 2021 0.09 0.10 0.14 Beat 47.4
Mar. 31 2021 0.10 0.10 0.13 Beat 30
Dec. 31 2020 0.11 0.11 0.07 Missed -33.3
Sep. 30 2020 0.10 0.10 0.11 Beat 10
Jun. 0.00 0.00 0.05 Beat 1,100
30 2020
Mar. 31 2020 0.12 0.15 0.18 Beat 20
Dec. 31 2019 0.21 0.21 0.30 Beat 46.3
Sep. 30 2019 0.16 0.16 0.23 Beat 48.4
This summary was machine generated October 27 at 15:01 GMT. All
figures in US dollars unless otherwise stated